Several big-name companies are racing to develop effective therapies for Alzheimer's disease (AD), a goal that has proven difficult over the years. It's no wonder that this area is attracting a lot of attention: About 5.8 million people in the U.S. had AD as of 2020. Some estimates put that number at 44 million worldwide.

Two drugmakers that feature in the race to find a successful AD treatment are Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB). Both healthcare giants have made progress over the past year. And within another 12 months, a lot could happen that could make or break their prospects; it will be an exciting time for investors.

But which of these companies has the best shot at remaining a leader in this therapeutic area from here on? And which is the better buy overall? Let's dig in and find out.

Continue reading

Source Fool.com